MACROH2A2 and breast cancer: SRGN, FLI1, and MACROH2A2 have undergone successful validation within the cohort of BC patients, demonstrating exceptional potential in robustly distinguishing healthy cohorts from BC patients and presenting implications in early diagnosis and prognostication of BC.